Nohla Therapeutics
Manufacturing · Washington, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1600 Fairview Ave E Ste 300, Seattle, Wa...Phone Number
(206) 519-5300Website
www.nohlatherapeutics.comRevenue
$42 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Nohla Therapeutics
Nohla Therapeutics is a leading developer of off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla's proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company's lead product candidate, dilanubicel, is currently under evaluation in two ongoing Phase 2 trials. Nohla is also pursuing multiple preclinical and discovery programs in the areas of immune tolerance and other diseases.Explore more
Nohla Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nohla Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Nohla Therapeutics has new funding data
Product Launch: Get notified when Nohla Therapeutics launches new products
Check out if Nohla Therapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Nohla Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Nohla Therapeutics
Website visits: Recent activity has been detected on your website
Nohla Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Nohla Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Nohla Therapeutics recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Nohla Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Nohla Therapeutics
Compare insights from companies similar to Nohla Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Nohla Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nohla Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nohla Therapeutics.
Nohla Therapeutics financials insights
Gather financial insights about Nohla Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$21M
Private Equity
$2M
2016
Series A
$43.5M
2017
Grant
$6.9M
2018
Series B
$56M
Nohla Therapeutics Tech Stack
Most Recent Scoops
Left Company
Management Move
Esther Cuno, Director, Human Resources, has left the organization.
Personnel Moves, Left Company
Left Company
Executive Move
Nicole Thai, Senior Director, Information Technology, has left the organization.
Executive Moves, Personnel Moves, Left Company
New Hire
Executive Move
Sarah Noonberg has been named Chief Medical Officer. In this role, Noonberg is responsible for overseeing medical and clinical strategy. Previously, she served at Prothena in the same role.
Executive Moves, New Hire, Personnel Moves
Lateral Move
Executive Move
Colleen Delaney, who previously served as Founder & Chief Medical Officer, has been named Founder & Chief Scientific Officer.
Executive Moves, Lateral Move, Personnel Moves
Funding
Funding
Nohla Therapeutics News & Media
Nohla Therapeutics Receives FDA Orphan Drug Designation for Dilanubicel for Hematopoietic Stem Cell Transplant Patients
SEATTLE, July 16, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nohla’s lead product candidate, dilanubicel (NLA101), Orphan Drug Designation for reduction of morbidity and mortality associated with hematopoietic stem cell transplant (HSCT). Dilanubicel received Orphan Drug Designation frNohla Therapeutics Raises Additional $11M in Second Close of $56M Series B
Nohla Therapeutics, a Seattle, WA-based developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, held the second $11M closing of its Series B financing, bringing the total amount raised in this round to $56m. New investors participating in the second closing included the University of Tokyo Edge Capital, Schroder […] The post Nohla Therapeutics Raises Additional $11M in Second Close of $56M Series B appeared first on FinSMEs.Nohla Therapeutics Announces Second Closing of $56 Million Series B Financing
Additional $11 Million Raised from Three New International Investors and One Existing Investor Additional $11 Million Raised from Three New International Investors and One Existing Investor
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nohla Therapeutics
Sign Up For FreeTo access detailed company insights
Nohla Therapeutics is a leading developer of off-the shelf cell therapies for patients with cancer and other critical diseases. Nohla's proprietary notch ligand technology platform serves as the foundation for its ongoing clinical, preclinical and discovery programs. The company's lead product candidate, dilanubicel, is currently under evaluation i... Read More
